1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Transition at Teva: Blockbuster drug Copaxone to lose patent protection in 2014

Introduction

In October 2013, Teva announced that it would be cutting approximately 10% of the workforce in order to cut costs. Later that month, it announced the departure of its CEO of just 18 months, Jeremy Levin, who was forced out by Chairman Phillip Frost. This case study looks out how Teva, one of the largest pharmaceuticals companies in the world, has ended up in this position, & what the future holds

Features and benefits

* This case study looks at Teva's operations and the market in which it operates. It also looks in detail at Copaxone, Teva's best-selling drug.
* The case study examines the M&A activity Teva has been involved in over recent years, and whether or not it has been successful.
* Teva's future engines of growth are discussed, as well as 2 outlooks for 2014, depending on generic competition for Copaxone.

Highlights

In the US, one in every seven prescriptions is filled with a Teva product, and in the UK, this rises to one in every six prescriptions. The company operates in over 60 countries worldwide and employs approximately 45,000 people. Teva has over 55,000 product variants and 1,000 molecules, and manufactured 64 billion tablets and capsules in 2013.
Copaxone is one of Teva's best-selling drugs, with global sales of $3.9bn in 2012 and $4.3bn in 2013. Copaxone accounted for 49% of the specialty drugs segment's sales in 2012, rising to 52% in 2013. However, Copaxone may face generic competition as early as May 2014.
The New Therapeutic Entities (NTE) program, launched in December 2012, uses existing, known molecules that can offer improvements for patients by being formulated, delivered or used in a novel way. Development of NTEs is less time consuming, less risky, and less expensive.

Your key questions answered

* Why is Copaxone losing patent protection and what is Teva doing to alleviate this?
* What is the NTE program?
* What is the outlook for Teva in 2014?

Table Of Contents

Transition at Teva: Blockbuster drug Copaxone to lose patent protection in 2014
OVERVIEW
Catalyst
Summary
TEVA PHARMACEUTICALS IS A LEADER IN GENERIC PHARMACEUTICALS
Teva is a global generics giant
Generic drugs are cheap and effective versions of branded drugs
Teva operates through three segments: generics, specialty, and other
Teva is a global powerhouse in generic medicine
The specialty segment is the second largest, with revenues of $8.4bn in 2013
The other segment accounts for 10% of sales
COPAXONE'S PATENT PROBLEMS AND POOR MandA ACTIVITY HAVE AFFECTED TEVA
Copaxone faces losing its patent in 2014
Teva is losing its patent early
Teva is attempting to move existing Copaxone patients to its new version
A string of questionable acquisitions has severely impacted Teva
NTE DEVELOPMENT AND INTEGRATED GENERIC AND RandD ORGANIZATION ARE PRIMARY ENGINES OF GROWTH
Teva's NTE program finds advances on existing therapies
The NTE program has several benefits which could propel growth for Teva
Teva is extremely optimistic about its NTE program
Analysts are unenthusiastic about Teva's strategy
Teva has an appetite for "game-changing deals"
TEVA IN TRANSITION
Change at Teva is causing ripples in the stock market
Teva anticipates two outlooks for 2014
The "Generic Copaxone" scenario assumes the launch of at least two generic competitors to Copaxone in June 2014
The "Exclusive Copaxone" scenario assumes no generic competition to Copaxone in June 2014
Teva is aggressive in its efforts to stave off generic competition
Teva plans to focus on NTE, RandD, and cost reduction
CONCLUSIONS
Teva has attempted to mitigate the loss of Copaxone's patent
APPENDIX
Definitions
Sources
Further Reading
Ask the analyst
About MarketLine
Disclaimer

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

  • $ 75000
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in both ...

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.